Based in Cranbury, New Jersey, Amicus Therapeutics is an American company that deals with biopharmaceuticals. The firm has developed advanced therapies to address rare and orphan diseases. Having gone public with its IPO in 2006 at NASDAQ Stock Exchange, the company has over the years developed a spectrum of treatment approached to address a variety of devastating human genetic problems.
With ATB200/AT2221 as their forefront biologics, which is a uniquely designed intervention for Pompe disease and applied alongside a pharmacological chaperone, Amicus Therapeutics has carved out a niche in the field of treating orphan diseases.
Migalastat, one of the company’s most robust interventions, is designed as an intervention for individuals suffering from late stages of Fabry disease in line with the patient’s genetic diagnosis. Another product candidate for late-stage development, SD-101, is a potential milestone therapy, the first-of-its-kind to treat the not so common connective tissue disease Epidermolysis Bullosa. Taking advantage of their biologics and utilizing the platform technologies of the Brandy Chaperone Advance Replacement Therapy, abbreviated as CHART, to develop new Enzyme Replacement Therapy interventions for the Pompe disease, Fabry disease, and similar lysosomal storage disorders. Know more on gcreport.com about Amicus Therapeutics.
Amicus Therapeutics got praised in 2004 as having possibly the broadest and most advanced portfolio of small molecules category of pharmacological chaperones. It was in 2008 when the company made a significant milestone in opening a new research center in San Diego to add to the one at New Jersey. Five years later Amicus would effect the acquisition of a rival company Callidus Biopharma which was a significant breakthrough especially in the development of the enzyme therapy intervention for the Pompe disease.
For 947 million dollars, the firm would acquire another of its competitors less than two years later, further advancing its dominance in the sector. John F. Crowley is both the CEO and the chairman of the board. Follow Amicus Therapeutics on Twitter.
Life Line Screening Company was founded in 1993 by Colin Scully and Timothy Phillips and is based in Austin, TX. It is a prevention and wellness company that is privately owned and operates health screening services that are community-based for adults across the USA. The company has conducted over eight million health screenings since it was founded, and it does over one million screenings per year. They carry out blood screenings, ultrasound scans, and electrocardiographs. The screenings are important because they ensure that diseases such as peripheral arterial disease, atrial fibrillation, and abdominal aortic aneurysm are detected early. The Better Business Bureau has accredited it since October 1996.
Their ultrasound screenings are painless and non-invasive, which is the same with their EKG for atrial fibrillation. When going for some screenings, you do not have to prepare much as compared to some screenings that require several hours of fasting while others require loose clothing or short sleeves only. Screening for Carotid artery disease requires the patient to wear a short-sleeved shirt that is open at the collar. Atrial fibrillation screening requires the patient to wear a two-piece outfit consisting of loose clothing, keep the cell phone turned off and do not wear pantyhose, watch or lotion or oil. Abdominal aortic aneurysm requires a two-piece outfit with loose clothing, fasting for four hours before the screening. However, for diabetic patients, they should stick to the recommended diabetic meal.
Ankle-brachial index screening requires the patient to wear a comfortable two-piece outfit with loose clothing, short-sleeved shirt or blouse and not to wear pantyhose. Complete lipid panel screening and glucose screening require fasting for eight hours before testing. 6 for life package require eight hours fasting before the screening, and the patient should wear a short-sleeved shirt. Bone mineral density patient only needs patient not to wear pantyhose. Patients going for elevated liver enzyme screening and hs-CRP(C-reactive protein) screening should not do anything in advance.
A board-certified physician reviews each screening apart from the 6 for life package as it is run through a clinically based predictive program. The patients receive a detailed report of their results within 21 days of their appointment through email or their online e-results program. Results are unique to the patient and signed by the reviewing physician and their National Medical Director. If a condition requires urgent attention, they inform the patient immediately. They also keep track of past screening history and remind the clients when it’s time to be re-screened.
To know more visit @: www.lifelinescreening.com/What-We-Do